Coronary/Structural Heart

Cardio Diagnostics Holdings, Inc and RiverRock Medical Partner to Bring Epigenetic-Genetic Heart Disease Testing to Austin, Texas

CHICAGO–(BUSINESS WIRE)–Cardio Diagnostics Holdings, Inc (Nasdaq: CDIO), a pioneer of artificial intelligence-driven precision cardiovascular medicine tests, announced a partnership with Austin, Texas-based concierge, and executive health practice, RiverRock Medical. This partnership establishes RiverRock Medical as the first service provider in Austin, Texas, to incorporate Epi+Gen CHD and PrecisionCHD, state-of-the-art epigenetic-genetic heart […]

Medtronic Statement on ESH Guidelines for Hypertension and Renal Denervation

DUBLIN–(BUSINESS WIRE)–Medtronic is excited by the updated European Hypertension Society (ESH) guidelines that highlight the role of renal denervation (RDN) as part of the hypertension care pathway. The guidelines were announced at the ESH 32nd Annual Meeting and simultaneously published in the Journal of Hypertension. This marks a turning point for RDN […]

BioCardia Completes Submission of CardiAMP Cell Therapy System in Heart Failure to Japan’s Pharmaceutical Medical Device Agency

SUNNYVALE, Calif. , July 05, 2023 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces it completed its submission of the CardiAMP Cell Therapy System to Japan’s Pharmaceutical and Medical Device Agency (PMDA) towards approval for the […]

FEops Receives FDA Clearance for Its AI-Based Anatomical Analysis Capabilities

Enabling a time-efficient workflow and better-informed clinical decision making for structural heart interventions GENT, Belgium–(BUSINESS WIRE)–FEops announced today its new release of FEops HEARTguide™, including an AI-based anatomical analysis of MSCT images for the pre-operative planning of structural heart interventions. With this introduction, physicians don’t need to do the measurements […]

Bioheart (02185.HK) announces clinical result for Iberis-HTN at CIT 2023

SHANGHAI, June 29, 2023 /PRNewswire/ — Bioheart (02185.HK), together with its holding subsidiary Angiocare announces the clinical result for Iberis-HTN at China Interventional Therapeutics 2023. Iberis-HTN is a prospective, multicenter, blinded, randomized controlled trial to evaluate the safety and efficacy of the Iberis® Multi-Electrode Renal Artery Radiofrequency Ablation Catheter System for the treatment […]

Alnylam Announces Date of Planned FDA Advisory Committee Meeting for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has set a date of September 13, 2023 for the meeting of the Cardiovascular and Renal Drugs Advisory Committee to review the supplemental New Drug Application for patisiran, an […]

PocDoc partners with NHS Targeted Lung Health Programme in North East, leveraging new biomarker Coronary Artery Calcium, to identify patients at increased risk of cardiovascular disease

CAMBRIDGE, England, June 29, 2023 /PRNewswire/ — PocDoc, the Cambridge-based digital health platform, today announces a major pilot with the NHS Targeted Lung Health Check programme in the North East, in partnership with cardiologist Dr Alan Bagnall and the NIHR Clinical Research Network North East and North Cumbria (CRN NENC). As documented widely in recent weeks, the NHS England Targeted […]

Kalos Medical Receives Korean MFDS Innovative Medical Device Designation for DENEX Hypertension Treatment System

SEOUL, Korea, June 28, 2023 (GLOBE NEWSWIRE) — Kalos Medical Inc. (“Kalos Medical”), a developer of innovative medical devices treating hypertension and other chronic illnesses, announced on June 23rd that South Korea’s Ministry of Food and Drug Safety (“MFDS”) designated the company’s DENEX hypertension treatment system as an Innovative Medical […]

CathWorks Announces First Patient Enrolled in Global ALL-RISE Study

Global clinical study aims to broaden evidence base by assessing clinical and economic benefits for the FFRangio System First patient enrolled at Ascension St. John Hospital in Michigan KFAR-SABA, Israel and IRVINE, Calif., June 28, 2023 /PRNewswire/ — CathWorks announced today that the first patient has been enrolled in the Advancing Cath Lab Results with FFRangio Coronary Physiology […]